Maralixibat for cystic fibrosis constipation
Treatments studied
Part of Digestive system, Genetic & congenital, Lungs & breathing clinical trials.
This trial tests a medicine called maralixibat to see if it helps children with cystic fibrosis who have chronic constipation that doesn't improve with standard treatments. The goal is to improve bowel movements and quality of life.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Child must be between 1 and 18 years old.
- Cystic fibrosis must be confirmed by a genetic test or sweat test.
- Chronic constipation (hard stools) must be present even with current treatment.
- Constipation treatment must be stable (no changes) for at least 4 weeks.
- No uncontrolled vitamin A, D, E, or K deficiency.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests how well cystic fibrosis (CF) medicine works for you using an “n-of-1” approach, meaning you try treatments in a structured, repeated way to see what helps you most. It may help your care team choose the best option for your specific CF genetics and health status.
This study tests an experimental inhalable medicine called ARCT-032 for people with cystic fibrosis who cannot take or benefit enough from current CFTR modulators. The goal is to see if it safely improves lung function and quality of life.
This study is following patients who are already taking Livmarli (maralixibat) for Alagille syndrome or PFIC to see how safe and effective it is over the long term.
This trial tests whether an oral medicine (eluxadoline) can help children and teens with IBS-D, a condition that causes stomach pain and frequent loose stools. It’s a Phase 3 study, meaning it’s designed to confirm benefits and safety.
This study looks at the long-term safety and effects of Livmarli (maralixibat) in children with Alagille syndrome or progressive familial intrahepatic cholestasis (PFIC). It may help understand how well the medicine works over time for itching and other symptoms.
This trial tests if the drug maralixibat can help women with a liver condition called intrahepatic cholestasis of pregnancy (ICP) that causes severe itching and high bile acids. If you are between 20 and 35 weeks pregnant with one healthy baby and have high bile acids, you may be able to join.
Hear when a new Constipation Chronic Idiopathic trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.